Spikevax (previously COVID-19 Vaccine Moderna)-H/C/PSUSA/00010897/202212: EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
Advanced pharmaceutical formulation for targeted therapeutic intervention.
Source
European Medicines Agency
Additional Information
medication.label.product_type
scientific-conclusion
medication.label.permit_number
EMA/371629/2023
medication.label.permit_validity
First published: 2023-09-07T14:05:00Z
Documents
Related Medications
Generic Class
Generic Class
Generic Class
Generic Class
Generic Class
Generic Class
Generic Class
Generic Class
AI Voice
Listen to the article content live